Posted by Michael Wonder on 24 Feb 2023
Recommendations made out of session by the PBAC November 2022 and March 2023 meetings
24 February 2023 - Recommendations made out of session by the PBAC between its November 2022 and March 2023 meetings are now available.
Actually, the PBAC made only one recommendation in this period.
The PBAC recommended extending the existing PBS listing of empagliflozin to include the treatment of patients with chronic heart failure with a left ventricular ejection fraction greater than 40%. Empagliflozin is listed on the PBS for the treatment of patients with chronic heart failure with a left ventricular ejection fraction under 40%.
